Premium
Enhanced oxidizability of ubiquinol and α ‐tocopherol during lovastatin treatment
Author(s) -
Palomäki Ari,
Malminiemi Kimmo,
Metsä-Ketelä Timo
Publication year - 1997
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(97)00609-1
Subject(s) - lovastatin , ubiquinol , tocopherol , chemistry , food science , biochemistry , vitamin e , antioxidant , cholesterol , coenzyme q – cytochrome c reductase , cytochrome c , mitochondrion
A double‐blinded, placebo‐controlled cross‐over trial was carried out with 27 hypercholesterolemic men with coronary heart disease. During the 6‐week treatment period lovastatin (60 mg/day) decreased fasting serum LDL cholesterol by 45%, LDL phosphorus by 38% and apoB by 33%. Ubiquinol content diminished by 13% as measured per LDL phosphorus. When LDL was oxidized ex vivo with AMVN both LDL ubiquinol and α ‐tocopherol were exhausted faster after lovastatin treatment compared to placebo, by 24% ( P <0.005) and 36% ( P <0.0001), respectively. Lag time in copper‐induced oxidation of LDL decreased by 7% ( P <0.01). This suggests diminished antioxidant‐dependent resistance of LDL to the early phase of oxidative stress.